Exclusive Summary

• - Patents expired and 1990s approvals enable broad generic entry; E. coli manufacturing eases tech transfer and fast scale-up.
• - Double-bolus IV push fits prehospital/low-resource settings, addressing ≥1–2 million STEMI candidates annually when PCI is delayed.
• - Non-inferior to alteplase on major outcomes with simpler administration; fibrinolysis is guideline-endorsed frontline when PCI is not timely.
• - Moderate competition: 10+ generic brands globally; lower immunogenicity than streptokinase and better affordability than tenecteplase in many markets.
• - Compliance and cost: aligned with USP/EP rDNA chapters, cold-chain ready, and 40–70% savings versus originator are achievable.

Asset Materials

Contact Us for Full Materials